Trial Profile
A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMbassador250
- Sponsors Roche
- 27 Jan 2024 Results (n=418) assessing early detection of and changes in ctDNA TF associated with clinical responses presented at the 2024 Genitourinary Cancers Symposium
- 18 Feb 2023 Results of ctDNA analysis assessing the association of ctDNA fraction, AR alterations and therapy outcome in metastatic castration-resistant prostate cancer, presented at the 2023 Genitourinary Cancers Symposium.
- 09 Feb 2023 This trial has been completed in Austria (End Date: 20 Dec 2022) according to European Clinical Trials Database record.